Roth Capital Partners raised its price target for Arch Therapeutics (OTCQB:ARTH) to $3 from $2.10 after the FDA cleared the company’s AC5 Topical Gel for use in partial and full-thickness skin wounds, such as pressure...

Canopy Growth (TSX:WEED; NYSE:CGC) entered into a multi-year extraction agreement with Valens GroWorks (CSE:VGW; OTC:MYMSF), a licensed provider of cannabis products and services focused on various extraction...

Leerink Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with an “outperform” rating and $24 price target. The stock closed at $9.64 on Dec. 12. Millendo is developing treatments for rare, debilitating...

H.C. Wainwright analyst Ed Arce assumed coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and price target of $2.50. The stock closed at $1.04 on Dec. 12. Organovo was founded in 2007 as a CRO, offering...

AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...

Maxim Group raised its price target for Quantum Genomics SA (Euronext Growth – FR0011648971 – ALQGC) to €9 from €6 after the company held a recent key opinion leader and investor day. The stock closed at €5...

Analysts at Canaccord Genuity and BTIG launched coverage of Vapotherm (NYSE:VAPO) with “buy” ratings and price targets of $25 and $26, respectively. The stock closed at $20.93 on Dec. 7. Vapotherm sells Precision Flow...

Stifel downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “hold” from “buy” and slashed its price target to $4 from $10 after the company’s ENCORE-PH trial missed its pre-specified primary endpoint. The stock closed at...

Echelon Wealth Partners upgraded ProMetic Life Sciences (TSX:PLI) to “speculative buy” from “hold” but reduced its price target to 60 cents from $1 after the company announced plans for Phase 3 testing of its anti...

Roth Capital Partners initiated coverage of BioSig Technologies (NASDAQ:BSGM) with a “buy” rating and $14 price target. The stock closed at $3.97 on Dec. 4. BioSig is a medical device company developing the PURE EP...

Roth Capital Partners launched coverage of CorMedix (NASDAQ:CRMD) with a “buy” rating and price target of $6. The stock closed at $1.35 on Dec. 4. CorMedix is developing Neutrolin for the prevention of catheter-related...

BTIG initiated coverage of Valeritas Holdings (NASDAQ:VLRX) with a “buy” rating and price target of $1. The stock closed at 39 cents on Dec. 3. Valeritas sells V-Go, the only pump on the market for Type 2 diabetes...

Maxim Group initiated coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $3 price target. The stock closed at 81 cents on Nov. 28.

JP Morgan launched coverage of Orchard Therapeutics (NASDAQ:ORTX) with an “overweight” rating and December 2019 price target of $25. The stock closed at $16.75 on Nov. 22. Analyst Anupam Rama writes that Orchard, in a...

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...

BTIG upgraded Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) to “buy” from “neutral,” with a $14 price target, after the company closed a $17.5-million stock offering. The stock closed at $8 on Nov. 19. Analyst Dr...

H.C. Wainwright analyst Joseph Pantginis assumed coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $18.50. The stock closed at $4.52 on Nov. 19. Caladrius is developing two...

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

Leerink Partners launched coverage of Assembly Biosciences (NASDAQ:ASMB) with an “outperform” rating and $45 price target. The stock closed at $24.67 on Nov. 16. “Our valuation and rating are based on our probability...

A.G.P./ Alliance Global Partners raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to 65 cents from 45 cents after the company’s third quarter results exceeded forecasts. The stock closed at 40 cents on...

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...